Information regarding the timing of abnormal detection of amyloid PET, plasma p-tau217, and tau PET in relation to preclinical cognitive decline suggests that an optimal window for secondary prevention of Alzheimer’s disease may be within ten years of amyloid PET positivity and within five years of plasma p-tau217 positivity. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.